Helius Medical Tech Analyst Ratings
Helius Medical Tech Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2022 | 809.09% | Roth Capital | → $5 | Initiates Coverage On | → Buy |
| 11/15/2021 | — | Noble Capital Markets | Downgrades | Outperform → Market Perform | |
| 03/24/2021 | 3536.36% | Noble Capital Markets | → $20 | Initiates Coverage On | → Outperform |
| 04/16/2019 | — | BTIG | Downgrades | Buy → Neutral | |
| 04/11/2019 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 03/06/2019 | — | Oppenheimer | Initiates Coverage On | → Outperform | |
| 11/20/2018 | 2445.45% | BTIG | → $14 | Upgrades | Neutral → Buy |
| 06/19/2018 | — | BTIG | Downgrades | Buy → Neutral | |
| 05/17/2018 | 2445.45% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 8 月 23 日 | 809.09% | 羅斯資本 | → 5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/15/2021 | — | 貴族資本市場 | 降級 | 跑贏大盤 → 市場表現 | |
| 2021 年 3 月 24 日 | 3536.36% | 貴族資本市場 | → 20 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 04/16/2019 | — | BTIG | 降級 | 買入 → 中性 | |
| 04/11/2019 | — | 奧本海默 | 降級 | 跑贏大盤 → 表現 | |
| 03/06/2019 | — | 奧本海默 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 11/20/2018 | 2445.45% | BTIG | → 14 美元 | 升級 | 中性 → 買入 |
| 06/19/2018 | — | BTIG | 降級 | 買入 → 中性 | |
| 05/17/2018 | 2445.45% | BTIG | → 14 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Helius Medical Tech Questions & Answers
Helius 醫療技術問題與解答
The latest price target for Helius Medical Tech (NASDAQ: HSDT) was reported by Roth Capital on August 23, 2022. The analyst firm set a price target for $5.00 expecting HSDT to rise to within 12 months (a possible 809.09% upside). 2 analyst firms have reported ratings in the last year.
羅斯資本於2022年8月23日公佈了Helius Medical Tech（納斯達克股票代碼：HSDT）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計HSDT將在12個月內升至12個月內（可能上漲809.09％）。去年有兩家分析公司公佈了評級。
The latest analyst rating for Helius Medical Tech (NASDAQ: HSDT) was provided by Roth Capital, and Helius Medical Tech initiated their buy rating.
羅斯資本對Helius Medical Tech（納斯達克股票代碼：HSDT）的最新分析師評級由羅斯資本提供，Helius Medical Tech啓動了買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Helius Medical Tech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Helius Medical Tech was filed on August 23, 2022 so you should expect the next rating to be made available sometime around August 23, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Helius Medical Tech的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Helius Medical Tech的最新評級是在2022年8月23日發佈的，因此您應該預計下一個評級將在2023年8月23日左右公佈。
While ratings are subjective and will change, the latest Helius Medical Tech (HSDT) rating was a initiated with a price target of $0.00 to $5.00. The current price Helius Medical Tech (HSDT) is trading at is $0.55, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Helius Medical Tech（HSDT）評級是啓動的，目標股價爲0.00美元至5.00美元。Helius Medical Tech（HSDT）目前的交易價格爲0.55美元，在分析師的預測區間內。